Aligned Genetics Valuation

Q: What is the Fair Price of A238120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A238120 (₩3215) is trading above our estimate of [[fair value]] (₩2612.1)

Is A238120 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A238120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A238120 (₩3215) is trading above our estimate of fair value (₩2612.1)

Significantly Below Fair Value: A238120 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A238120?

Key metric: As A238120 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A238120. This is calculated by dividing A238120's market cap by their current earnings.
What is A238120's PE Ratio?
PE Ratio	18.7x
Earnings	₩2.48b
Market Cap	₩45.37b

A238120 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.2x
Enterprise Value/EBITDA	10.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A238120's PE Ratio compare to its peers?

The above table shows the PE ratio for A238120 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	12.6x
A347740 P&K Skin Research Center	11.5x	n/a	₩63.3b
A359090 C&R Research	12.6x	n/a	₩65.8b
A215380 WOOJUNG BIO	23.7x	n/a	₩27.6b
A331920 Celemics	2.6x	n/a	₩28.7b
A238120 Aligned Genetics	18.7x	n/a	₩45.4b

Price-To-Earnings vs Peers: A238120 is expensive based on its Price-To-Earnings Ratio (18.7x) compared to the peer average (12.6x).

Price to Earnings Ratio vs Industry

How does A238120's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A238120 is good value based on its Price-To-Earnings Ratio (18.7x) compared to the Asian Life Sciences industry average (32.4x).

Price to Earnings Ratio vs Fair Ratio

What is A238120's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A238120 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	18.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A238120's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.9%

-20.6%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩272,000.00

-3.5%

79.4%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,540.00

3.6%

n/a